on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TY ...I am not still in....my wife had a big thing to do with that
I did however walk away with $40 grand + ....I believe this is way overbought and is due to make a correction as they say....It will prob gap in am and run for perhaps firt 30 min. or so but I believe most will take profits and move on to the next play- he buying here is mostly I.H. daytraders and most are not looking for long term holds.....I would not base your decision on my opinion though....I do Believe this is a Long Long term Hold-
The one concern I have is them increasing the Authorized shares to make this more liquid.
Who knows ....this may run to $1 - anything possible in Pennyland
Remember that Amgen Co-founder did buy a million shares last month so he has to benefit also with pps rise and he had them converted so he could sell them quickly. IMO This is penny land and with one negative pr. could plummet back to under a penny very quickly
You should post the aquisition prices also
Athera has two years' cash on hand. However, Anthera could partner before phase 3 starts, now that they [i]have received sign-offs from both the FDA and Europe. The data that will be presented at ACR will also help fuel the partnership process.
November 13th....next week should get interesting along with the rest of this week
The phase 3 trials, the ACR meeting and a good management team provide excellent catalysts in the coming months.
Anthera's phase 2 dose-ranging data was complicated and lacked statistical significance. However, the company found that the drug candidate is very active in sicker patients. Anthera has designed the clinical trials and obtained sign-off from both the FDA and the European regulatory authorities to start phase 3 late this year or early next year. We should get some additional data at the American College of Rheumatology [ACR] meeting in November.
Start accumulating for major move imo
DATA COMING OUT November 13th
Anthera's B-cell molecule product, targeting lupus, appears to be an improvement over GlaxoSmithKline's (GSK) Benlysta [belimumab].
If Anyone is interested in any more DD and which is easier to understand you may go to my past posts- just make sure you Mark (follow) me as I spent Many hrs of research on this Co. It will only cost you a click of a mouse ....LOL Just click on One2WatchIMSC to get to my past posts
GLTA
They own Patent rights here and in Europe
You should take some time to do some DD before buying in.....I personally think it is too risky to buy in at these levels if you want short term gains....It may go up 50% from here.....but will be hard to sell if you buy millions. It was difficult for me to sell but with the BUZZ around here it was done. I got in at the bottom -.005
Gotta go....bought a hefty load of VR*G today....
\GLTY
It is a Father Son Company....you don't have to bash it if you want in.....I'm sure it will come down without the bashing. If you listen or watch the videos you can listen to the Ceo/ ex- football player speak- He is well spoken and knows what he's talking about
Their are several phases a drug must go through to get FDA approval. when it reaches Phase II ...thats when investors get really excited when good results come out. Tramatic Brain Injury is already being researched and has had positive results....this was beginning of 2012 when they parntered up with Banyon ....The info is all here
You should be able to sell and buy at lower prices soon...its pumped up
was a nice day for me....picked up 7000 shares @ 3.30- Not sure if I can hold out for the news.....hopefully this hits $5 before any news....shouldn't be a problem in the AM
Manf is a protein in which reverses cell death which happens in most if not all diseases. Parkinson is just what they are concentrating on now. The key is to catch these diseases in their early stages. This is where Nuropro comes in....Blood test for Parkinson and should be helping them with revenue in 1st quarter of 2013 if all goes well. In Biotechs the approval process with FDA is very long and expensive...Years
But we are entering Pharmageddon so this is going to be a breakthrough and all the pieces are falling into place.
GLTA
Press conferences are an opportunity for invited investigators to share their findings with members of the media. Press conferences are not open to the public; however, up to two representatives of each company may attend press conferences (which are held in space distinct from the Newsroom), but must remain silent and must check-in with Newsroom staff prior to entering the press conference.
maybe the press will do a review of the Company
http://www.acrannualmeeting.org/Press
I guess the Doc will presenting all day.
Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Presenter: Richard A. Furie: North Shore-Long Island Jewish Health System
Date: Tuesday, November 13
Time: 9:00 AM - 6:00 PM
Location: Poster Hall (Hall B)
Session Title: ACR Late-breaking Abstracts Poster Session
Category: Late-Breaking Abstracts
just bought some...
ready for the ride
I just picked up some....They have to have some positive results going to a show with 16,000 attending- should be a nice gain from here
when is the R/S
that"s good to hear...i do know they were diluting a couple weeks ago- when it was at .005 and I snatched up almost a couple million. I believe the outstanding was up to 160 mil.(not that that its a lot) if I remember correctly.I would like to jump back in also but if I have to wait until the hype cools down ----there are many other plays out there. I couldn't resist selling in the .03 to .035 range- just tooo much $ on the table and I have a feeling it's going to come back down since it went up so quickly. I was hoping for a slow steady increase but I was thrilled with almost 40 grand in 2 days almost a record for me personally----except for back in 2005 with QBID and last run with LKEN
Maybe I should just take a vacation to Fiji- I hear it's nice there
Den - have you called the TA recently for the outstanding now?
Carrier Alliance Group has been in business for 6 years with billings in excess of $5 million US and is a profitable operation, the business model will be to grow the company through a series of identified acquisitions to attain critical mass and cost savings
just took a small position just before the bell....thanks Den
I would advise everyone to watch or listen to the videos to better understand the Co.. You will get very excited or at least I did
Amarantus BioSciences is interested in partnering opportunities for its product candidates that will allow development of adjunct -products that will address diseases caused by poorly served biological pathways. We intend to generate revenues through collecting up-front and milestone payments as our candidates advance through pre-clinical and clinical development, and royalties upon commercialization.
They are doing just that
“The fundamental progress the Company has made since our First Annual CEO Letter was released in May has been quite significant. We have achieved the following milestones:
1. Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
Acute Myocardial Infarction
Approximately 800,000 events of acute myocardial infarction occur in the US each year and, despite all of the advances in medicine and intervention, about 20% or approximately 160,000 patients have a ST-Elevation MI (STEMI) resulting in a reduced Left Ventricular Ejection Fraction (LVEF) of less than 50%. That means that their MI was big enough and their heart so damaged that the remaining heart muscle could not compensate for the damaged heart tissues and, over time, the hearts starts to fail. These patients are at significant risk of downstream adverse events including congestive heart failure, re-current MI, significant arrhythmias, premature death or acute coronary syndrome
2. Secured the license for the NuroPro Parkinson’s diagnostic blood test; and
3. Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
http://www.businesswire.com/news/home/20101005005193/en/Banyan-Biomarkers-Awarded-26.3-Million-Department-Defense
get ready to go over HOD
and Parkinson's is just the Tip of the Iceberg
There are numerous other uses for their patented MANF. I believe it will be a GAME CHANGER in the whole Biotech Sector
Received Grant from them
The University of Massachusetts Amherst is well-known for its breadth of research expertise in apoptosis, or programmed cell death. This important biological process is known to play a significant role in a wide range of devastating health problems, including cancer, neurodegenerative disorders, type 1 diabetes, and reperfusion injuries following heart attacks and strokes.
With funding from the Massachusetts Technology Collaborative's John Adams Innovation Institute, we launched the Center of Excellence in Apoptosis Research (CEAR) in 2006. Located at PVLSI, the center crosses disciplines to create research groups that focus on signaling pathways that regulate apoptosis. The teams then use their findings to develop new diagnostic tools and therapies to treat human disease.
Former executive from Bristol Myers
Clinton says
"I am very excited to join Amarantus at this critical time in its growth cycle," said Clinton O. Allen, newly appointed advisor to Amarantus. "The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order meticulously evaluate proposals and make recommendations for future growth."
Most exciting thing is MANF is potential cure for many diseases that kill.....not just Parkinson's.....but Amarantus has to concentrate on one at a time until new partners are acquired
$AMBS "THE CURE-MAKER"with 1000's of studies over the years from independent researchers of Manf and AMARANTUS having a patent on it until 2031 ....even before it is FDA approved it is worth 30 times what the Market Cap. is now and they own many other patents too. The co. has spent over 30 MILLION in research already from a report I read a couple weeks ago.
Amarantus' license for NuroPro, our clinical-stage Parkinson's disease diagnostic blood test, has several potential positive benefits for our MANF Parkinson's program including the identification of patients most likely to respond to MANF treatment. We intend to immediately pursue a partnering strategy for NuroPro and expect to update the marketplace once definitive agreements are reached. NuroPro could become a significant source of revenue for the Company within a relatively short period of time and its further development could have a major impact on the way Parkinson's disease is diagnosed and managed by physicians.
7 to 10 cents soon!
IMO
http://adage.com/article/agency-news/agencies-plan-survive-pharmageddon/237031/
As Drugs Fall Off Patent Cliff, Agencies Are Rethinking Health Care With New Practices, Approaches
By: Alexandra Bruell Published: September 10, 2012
Parkinson cure is just the beginning .....MANF will cure many other diseases too! They have a medical breakthrough
Amarantus BioSciences Co-Founders honored among 2012’s
“50 Most Important African-Americans in Technology”
SUNNYVALE, CA – September 25, 2012 – Amarantus Biosciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing new treatments and diagnostics for Parkinson’s disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com‘s 13th annual “50 Most Important African-Americans in Technology” for 2012. The selectees will gather in Washington, D.C. January 15th, 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).
Amgen spends $2.7 billion a year on research
http://www.bloomberg.com/news/2012-01-26/amgen-agrees-to-purchase-micromet-for-1-16-billion-to-gain-leukemia-drug.html
March 7, 2012
Amgen Completes Acquisition Of Micromet For $1.16 Billion
http://www.researchviews.com/healthcare/pharma/immunology/DealReport.aspx?sector=Immunology&DealID=185954
Amgen buying Turkey's Mustafa Nevzat for $700M
http://finance.yahoo.com/news/amgen-buying-turkeys-mustafa-nevzat-103141964.html
THOUSAND OAKS, Calif. (AP) -- Amgen Inc. is buying Turkish pharmaceutical company Mustafa Nevzat Pharmaceuticals
for $700 million as part of its international expansion plans.
Amgen Closes $315M Buyout of KAI Pharmaceuticals
http://www.pharmpro.com/News/2012/07/Business-Amgen-Closes-315M-Buyout-of-KAI-Pharmaceuticals/
THOUSAND OAKS, Calif. (AP) — Amgen Inc. said Thursday it completed its acquisition of KAI Pharmaceuticals for $315 million.